Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 453

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 453
---
 of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned
    at least 85% of our voting shares outstanding at the time the transaction commenced; or

    ●
    At
    or subsequent to the time that such shareholder became an interested shareholder, the affiliated transaction is approved by our board
    of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote
    of at least two-thirds of the outstanding voting shares which are not owned by the interested shareholder.

An
“interested shareholder” is generally defined as any person who is the beneficial owner of more than 15% of our outstanding
voting shares.

The
voting requirements set forth above do not apply to a particular affiliated transaction if one or more conditions are met, including,
but not limited to, the following: if the affiliated transaction has been approved by a majority of our disinterested directors; if we
have not had more than 300 shareholders of record at any time during the three years preceding the date the affiliated transaction is
announced; if the interested shareholder has been the beneficial owner of at least 80% of our outstanding voting shares for at least
three years preceding the date the affiliated transaction is announced; or if the consideration to be paid to the holders of each class
or series of voting shares in the affiliated transaction meets certain requirements of the statute with respect to form and amount, among
other things.

Both
the control share acquisition statute and the affiliated transactions statute may have the effect of discouraging or preventing certain
change of control or takeover transactions involving us.

In
addition, our amended and restated articles of incorporation and amended and restated bylaws contain provisions that may make it more
difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our shareholders, including
transactions in which shareholders might otherwise receive a premium for their shares. These provisions include:

    ●
    nothing
    in our amended and restated articles of incorporation precludes future issuances without shareholder approval of the authorized but
    unissued shares of our common stock;

    ●
    advance
    notice procedures apply for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting
    of shareholders;

    ●
    a
    special meeting of shareholders can only be called by our chairman of the board of directors, our chief executive officer, our president
    (in the absence